Clinical trial
An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
NCT05259319 is registered in ClinicalTrials.gov with Centre Georges Francois Leclerc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
- Lead sponsor
- Centre Georges Francois Leclerc
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 5, 2022
- Completion date
- December 5, 2024
- Enrollment
- 92 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic bladder cancer, metastatic head and neck cancer, metastatic non small cell lung cancer, metastatic renal cell carcinoma